ArticleFrontiers in pharmacology2026
Fisetin promotes skin wound healing and inhibits pathological scar formation through modulation of the PI3K/Akt/TGF-β1 signaling axis.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: During the healing of skin wounds, excessive fibrosis and collagen remodeling disorders often lead to the formation of proliferative scars. Fisetin is a naturally occurring flavonoid compound with antioxidant and anti-fibrotic properties. However, its therapeutic effect and mechanism of action in wound healing and inhibition of scar formation are still unknown. Methods: This study used network pharmacological methods to identify potential targets and pathways related to wound healing and proliferative scar formation. Through protein-protein interaction analysis, Gene Ontology analysis and enrichment analysis of the Kyoto Encyclopedia of Genes and Genomes (KEGG), its potential biological functions were clarified. In addition, molecular docking was also carried out to evaluate the binding affinity between fisetin and the core target. The effect of fisetin on wound closure and collagen deposition was evaluated using the full-thickness skin wound model in rats. In in vitro experiments, human dermal fibroblasts were used to study the effect of fisetin on collagen expression and the phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway. Results: Network pharmacological analysis highlighted serine/threonine kinase 1 (AKT1) as a central target linking fisetin to wound repair and fibrosis. Functional enrichment indicated significant involvement of the PI3K/Akt pathway. Molecular docking further confirmed a strong binding affinity between fisetin and AKT1. Conclusion: Fisetin promotes skin wound healing and attenuates proliferative scar formation by reducing inflammation, improving collagen remodeling, and suppressing fibrotic signaling. Mechanistically, fisetin upregulates PTEN and inhibits the PI3K/Akt/TGF-β1 axis, thereby limiting fibroblast activation and pathological extracellular matrix deposition. These findings suggest fisetin as a promising therapeutic candidate for wound management and scar prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.